Pharmacoclinical study of the action of vinburnin versus placebo: study of the hemodynamic, microcirculatory and rheological effects in angiopathy of the lower limbs in diabetes mellitus.
The diabetic macroangiopathy of lower limbs in characterized by chronic hypoxia with several abnormalities of hemodynamic, microcirculatory, rheological and metabolic red cell parameters. This study, in a double blind test with placebo was carried out on 40 subjects: 20 normal subjects and 20 diabetic patients suffering from microangiopathy of lower limbs. Ten are treated by 45 mg iv per day of Vinburnin, the 10 others received a placebo. Before and after treatment, the following parameters were measured: arterial flow rate at rest and after hyperhemia, transcutaneous oxygen level (TCpO2), red cell deformability, plasma viscosity, fibrinogen, red cell 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP). In this study, we have proved several effects of Vinburnin on the microcirculatory and rheological parameters the most essential for the transport of oxygen. The significant improvement of TCpO2, of ATP and 2,3-DPG red cell levels, of plasma viscosity and red cell deformability, even though we have no haemodynamic changes, confirm the rheological effects of Vinburnin. These pharmacological properties prove the interest and the special position of Vinburnin in the treatment of vascular diseases with acute or chronic tissular hypoxia.
Le Devehat
C
C
Unité de Recherches d'Hémorhéologie Clinique, Centre Hospitalier de Nevers, Pougues les Eaux, France.
Vimeux
M
M
D000328:Adult; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D010919:Placebos; D012039:Regional Blood Flow / Q000187:drug effects; D012212:Rheology; D014665:Vasodilator Agents; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D010919:Placebos; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C016422:eburnamonine